Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SIMVASTATIN Cause End stage renal disease? 85 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 85 reports of End stage renal disease have been filed in association with SIMVASTATIN (Simvastatin). This represents 0.3% of all adverse event reports for SIMVASTATIN.

85
Reports of End stage renal disease with SIMVASTATIN
0.3%
of all SIMVASTATIN reports
70
Deaths
70
Hospitalizations

How Dangerous Is End stage renal disease From SIMVASTATIN?

Of the 85 reports, 70 (82.4%) resulted in death, 70 (82.4%) required hospitalization, and 69 (81.2%) were considered life-threatening.

Is End stage renal disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SIMVASTATIN. However, 85 reports have been filed with the FAERS database.

What Other Side Effects Does SIMVASTATIN Cause?

Myalgia (3,919) Fatigue (2,066) Arthralgia (1,775) Drug interaction (1,744) Nausea (1,676) Rhabdomyolysis (1,616) Dyspnoea (1,542) Headache (1,470) Drug hypersensitivity (1,433) Muscular weakness (1,356)

What Other Drugs Cause End stage renal disease?

OMEPRAZOLE (10,356) ESOMEPRAZOLE (10,231) LANSOPRAZOLE (9,734) PANTOPRAZOLE (8,523) DEXLANSOPRAZOLE (4,800) RABEPRAZOLE (1,295) EMTRICITABINE\TENOFOVIR DISOPROXIL (721) TENOFOVIR DISOPROXIL (558) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (462) TACROLIMUS (361)

Which SIMVASTATIN Alternatives Have Lower End stage renal disease Risk?

SIMVASTATIN vs SINGULAIR SIMVASTATIN vs SINTILIMAB SIMVASTATIN vs SIPONIMOD SIMVASTATIN vs SIPULEUCEL-T SIMVASTATIN vs SIROLIMUS

Related Pages

SIMVASTATIN Full Profile All End stage renal disease Reports All Drugs Causing End stage renal disease SIMVASTATIN Demographics